Toxicity associated with carboplatin/paclitaxel/Irinotecan use in advanced ovarian cancer: preliminary analysis.

Oncology (Williston Park, N.Y.)

Volumn 17, Issue 5 Suppl 5, 2003, Pages 34-35

  Markman, Maurie ^a   Zanotti, Kristine ^a   Webster, Kenneth ^a   Belinson, Jerome ^a   Rose, Peter ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOPLATIN; DRUG DERIVATIVE; IRINOTECAN; PACLITAXEL;

ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; OVARY TUMOR; PHASE 2 CLINICAL TRIAL; WOMEN'S HEALTH;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; WOMEN'S HEALTH;

EID: 0141783775     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)